Abstract
Hormonal therapy began to be used for endometrial carcinoma after Kelley and Baker (1961) reported that endometrial cancer responded to progestational therapy. Multiple empirical trials of progestational agents in the treatment of this disease were reported during the next two decades. Various response rates were recorded, most between 30% and 50% (Bonte et al. 1978; Geisler 1973; Malkasian et al. 1971; Piver et al. 1980; Rozier and Underwood 1974; Smith et al. 1966; Wait 1973). At least part of the variability in these rates undoubtedly reflected differences in how stringently tumor response was defined. Although complete resolution of systemic disease (for example, multiple pulmonary metastatic lesions) for extended periods can occur with hormonal therapy, such responses unfortunately are exceptions to the norm.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Benraad TJ, Friberg LG, Koenders AJM, Kullander S (1980) Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy? Acta Obstet Gynecol Scand 59: 155
Bonte J, Decoster JM, Ide P, Billiet G (1978) Hormonoprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate. Gynecol Oncol 6: 60
Bonte J, Janssens JP, Ide P (1986) Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology. Eur J Gynaecol Oncol 7: 45
Carlson JA Jr, Allegra JC, Day TG Jr, Wittliff JL (1984) Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 149: 149
Creasman WT, McCarty KS Sr, Barton TK, McCarty KS Jr (1980) Clinical correlates of estrogen-and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 55: 363
Creasman WT, Soper JT, McCarty KS Jr, McCarty KS Sr, Hinshaw W, Clarke-Pearson DL (1985) Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 151: 922
Edmonson JH, Krook JE, Hilton JF, Long HJ III, Cullinan SA, Everson LK, Malkasian GD (1986) Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure. of progestin treatment. Cancer Treat Rep 70: 1019
Ehrlich CE, Young PCM, Stehman FB, Sutton GP, Alford WM (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158: 796
Geisler HE (1973) The use of megestrol acetate in the treatment of advanced malignant lesions of the endometrium. Gynecol Oncol 1: 340
Kauppila A, Friberg L-G (1981) Hormonal and cytotoxic chemotherapy for endometrial carcinoma: steroid receptors in the selection of appropriate therapy. Acta Obstet Gynecol Scand [Suppl] 101: 59
Kauppila A, Kujansuu E, Vihko R (1982) Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with surgery, radiotherapy, and progestin: clinical correlates. Cancer 50: 2157
Kelley RM, Baker WH (1961) Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 264: 216
Kline RC, Freedman RS, Jones LA, Atkinson EN (1987) Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Cancer Treat Rep 71: 327
Liao BS, Twiggs LB, Leung BS, Yu WCY, Potish RA, Prem KA (1986) Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma. Obstet Gynecol 67: 463
Malkasian GD Jr, Decker DG, Mussey E, Johnson CE (1971) Progestogen treatment of recurrent endometrial carcinoma. Am J Obstet Gynecol 110: 15
Malkasian GD Jr, McDonald TW, Pratt JH (1977) Carcinoma of the endometrium: Mayo Clinic experience. Mayo Clin Proc 52: 175
Malkasian GD Jr, Annegers JF, Fountain KS (1980) Carcinoma of the endometrium: stage I. Am J Obstet Gynecol 136: 872
Martin PM, Rolland PH, Gammerre M, Serment H, Toga M (1979) Estradiol and progesterone receptors in normal and neoplastic endometrium: correlations between receptors, histopathological examinations and clinical responses under progestin therapy. Int J Cancer 23: 321
Mortel R, Levy C, Wolff J-P, Nicolas J-C, Robel P, Baulieu E-E (1981) Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen. Cancer Res 41: 1140
Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate ( Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45: 268
Podratz KC, O’Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH (1985) Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66: 106
Pollow K, Manz B, Grill H-J (1983) Estrogen and progesterone receptors in endometrial cancer. In: Jasonni VM, Nenci I, Flamigni C (eds) Steroids and endometrial cancer, vol 25. Raven Press, New York, pp 37–60
Quinn MA, Cauchi M, Fortune D (1985) Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 21: 314
Rozier JC Jr, Underwood PB Jr (1974) Use of progestational agents in endometrial adenocarcinoma. Obstet Gynecol 44: 60
Smith JP, Rutledge F, Soffar SW (1966) Progestins in the treatment of patients with endometrial adenocarcinoma. Am J Obstet Gynecol 94: 977
Swenerton KD, Chrumka K, Paterson AHG, Jackson GC (1984) Efficacy of tamoxifen in endometrial cancer. Prog Cancer Res Ther 31: 417
Wait RB (1973) Megestrol acetate in the management of advanced endometrial carcinoma. Obstet Gynecol 41: 129
Zaino RJ, Satyaswaroop PG, Mortel R (1985) Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Res 45: 539
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin·Heidelberg
About this paper
Cite this paper
Podratz, K.C. (1990). Hormonal Therapy in Endometrial Carcinoma. In: Beck, L., Grundmann, E., Ackermann, R., Röher, HD. (eds) Hormone-Related Malignant Tumors. Recent Results in Cancer Research, vol 118. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83816-3_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-83816-3_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83818-7
Online ISBN: 978-3-642-83816-3
eBook Packages: Springer Book Archive